ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Aegerion Pharmaceuticals, Inc." (AEGR) Report Updated: Dec 15, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Aegerion Pharmaceuticals, Inc." (AEGR)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: REGN, CBST, ANAC, FOLD

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: F down downgrade
Last Week: D same upgrade
Two Weeks Ago: F up no change
service keys

"Aegerion Pharmaceuticals, Inc."© quotemedia

Company Profile

Aegerion Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases. The company focuses on therapeutics to treat severe inherited lipid disorders. Lipids are naturally occurring molecules, such as cholesterol and triglycerides that are transported in the blood. Its lead product, lomitapide has completed pivotal Phase III clinical trial to treat patients with a rare inherited lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The company also plans to develop lomitapide for the treatment of adult patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Recent News: "Aegerion Pharmaceuticals, Inc."